Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Avenacy Announces U.S. Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection

therapy during and following tooth extraction. Each vial of Tranexamic Acid in 0.7% Sodium Chloride Injection contains 1,000 mg per 100 mL (10 mg per mL) and is available as a carton of 10 single-dose ready-to-use vials. “We are proud to continue...

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

Significantly fewer individuals with detectable blood UMFA in the 5-MTHF group (7%) compared with the folic acid group (31%).†* Lower UMFA concentrations in maternal blood and in the placenta, among those taking 5-MTHF.†* †Based on a 24-week,...

Viralgen Teams with Elaaj Bio to Advance CDKL5 Deficiency Gene Therapy

and the Loulou Foundation, we're uniting complementary strengths in development and manufacturing to help accelerate ELJ-101 toward clinical development." CDKL5 Deficiency Disorder (CDD) is a rare and severe developmental and epileptic...

Amazon Pharmacy Expands Same-Day Delivery and Kiosk Access for New Ozempic® Pill

directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and pickup within minutes through...

Study Finds Testosterone Therapy Boosts Women’s Energy, Mood, and Quality of Life

Joi + Blokes, a telehealth platform specializing in diagnostic testing, personalized medicine, and hormone and menopause care, announced the publication of a new peer-reviewed study demonstrating that testosterone replacement therapy (TRT) in...

BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) Execute Heads of Terms to Accelerate Global Expansion of CAR T-Cell Therapy

under which BioOra secures global rights to develop and commercialise Wellington Zhaotai's novel third-generation anti-CD19 CAR T-cell therapy for the treatment of multiple conditions (WZTL-002), including haematological malignancies and...

NurtureBio Launched Breast Milk–Inspired Synbiotic to Help Babies with Gut Issues

NurtureBio, a new maternal and child wellness company focused on emerging scientific solutions to gut health issues, today announced its official launch and the release of its first product: a synbiotic supplement. This synbiotic features human...

Elizabeth Nanouris Named VP of Business Operations at InFocus Clinical Research

About InFocus Clinical Research InFocus Clinical Research is the only global full-service retina-focused CRO. Founded in 2014, and having offices in Australia, China, Europe, Latin America and the United States; InFocus is the premier for pharma...

TruLeaf Medical Completes Second-Stage Valve Implantation in Two Patients

TruLeaf Medical, Ltd, a fully-owned subsidiary of Allmed Solutions (TASE: ALMD), a clinical-stage medical device company specializing in transcatheter structural heart innovations, is pleased to announce the successful completion of the full...

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...

Incyte announces FDA approval of Jakafi XR for treating myelofibrosis, polycythemia vera, and graft-versus-host disease

vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two...

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

designed to maintain cytotoxicity while limiting cytokine release, cizutamig has been clinically evaluated in over 100 patients with multiple myeloma and autoimmune diseases and is currently in multiple clinical studies in over 10 autoimmune...

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the...

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now available in a 15-count carton....

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

Infusor for subcutaneous delivery of furosemide meets the General Safety and Performance Requirements (GSPRs) of EU MDR 2017/745. CE Marking is a prerequisite for marketing medical devices within the EU and is recognized in numerous other countries...

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

of Defense (DoD) and will begin commercial deployment of its FDA-cleared wound treatment, Hemastyl®, starting May 1, 2026. Clinical training across VA and DoD facilities will begin May 1, marking the company's first large-scale entry into...

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading AAV capsid that leverages human transferrin receptor 1 (hTfR1) to enable intravenous delivery to the brain and...

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

to severely active Crohn's disease (CD). "Crohn's disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reaches beyond the gut as its unpredictability can impact daily life and emotional...

Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable...

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia. Aplastic anemia, a rare and life-threatening blood disorder,...